BIOTECHNOLOGY VALUE FUND L P - Jan 24, 2025 Form SCHEDULE 13G Schedule Report for Monte Rosa Therapeutics, Inc. (GLUE)

Filing Manager
BIOTECHNOLOGY VALUE FUND L P
Reporting Manager
BVF PARTNERS L P/IL
Security
Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol
GLUE
Shares outstanding
61M shares
Disclosed Ownership
4.39M shares
Ownership
7.2%
Form type
SCHEDULE 13G
Date filed
1/31/2025, 06:43 PM
Date of event
Jan 24, 2025
SEC
View on sec.gov

Reporting Managers (10)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BIOTECHNOLOGY VALUE FUND L P 3.7% 2.26M 0 2.26M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF I GP LLC 3.7% 2.26M 0 2.26M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BIOTECHNOLOGY VALUE FUND II LP 3% 1.82M 0 1.82M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF II GP LLC 3% 1.82M 0 1.82M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
Biotechnology Value Trading Fund OS LP 0.4% 228K 0 228K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF Partners OS Ltd. 0.4% 228K 0 228K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF GP HOLDINGS LLC 6.6% 4.08M 0 4.08M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF PARTNERS L P/IL 7.2% 4.39M 0 4.39M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF INC/IL 7.2% 4.39M 0 4.39M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
LAMPERT MARK N 7.2% 4.39M 0 4.39M /s/ Mark N. Lampert Mark N. Lampert